Syndax Pharmaceuticals (SNDX) Competitors $16.38 +0.39 (+2.44%) Closing price 04:00 PM EasternExtended Trading$16.32 -0.05 (-0.34%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SNDX vs. GRFS, TGTX, KRYS, SWTX, BHVN, RXRX, PTCT, OGN, RARE, and ALVOShould you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Grifols (GRFS), TG Therapeutics (TGTX), Krystal Biotech (KRYS), SpringWorks Therapeutics (SWTX), Biohaven (BHVN), Recursion Pharmaceuticals (RXRX), PTC Therapeutics (PTCT), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry. Syndax Pharmaceuticals vs. Grifols TG Therapeutics Krystal Biotech SpringWorks Therapeutics Biohaven Recursion Pharmaceuticals PTC Therapeutics Organon & Co. Ultragenyx Pharmaceutical Alvotech Grifols (NASDAQ:GRFS) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment. Does the media refer more to GRFS or SNDX? In the previous week, Syndax Pharmaceuticals had 2 more articles in the media than Grifols. MarketBeat recorded 6 mentions for Syndax Pharmaceuticals and 4 mentions for Grifols. Syndax Pharmaceuticals' average media sentiment score of 0.51 beat Grifols' score of 0.27 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Syndax Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, GRFS or SNDX? Grifols has higher revenue and earnings than Syndax Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.13B0.72$64.20MN/AN/ASyndax PharmaceuticalsN/AN/A-$209.36M-$3.63-4.51 Is GRFS or SNDX more profitable? Grifols' return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A Syndax Pharmaceuticals N/A -64.34%-57.72% Do analysts rate GRFS or SNDX? Syndax Pharmaceuticals has a consensus price target of $36.20, suggesting a potential upside of 121.00%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90 Which has more risk and volatility, GRFS or SNDX? Grifols has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Does the MarketBeat Community believe in GRFS or SNDX? Syndax Pharmaceuticals received 37 more outperform votes than Grifols when rated by MarketBeat users. Likewise, 65.37% of users gave Syndax Pharmaceuticals an outperform vote while only 56.09% of users gave Grifols an outperform vote. CompanyUnderperformOutperformGrifolsOutperform Votes35056.09% Underperform Votes27443.91% Syndax PharmaceuticalsOutperform Votes38765.37% Underperform Votes20534.63% SummarySyndax Pharmaceuticals beats Grifols on 8 of the 13 factors compared between the two stocks. Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNDX vs. The Competition Export to ExcelMetricSyndax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.40B$7.05B$5.80B$8.95BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-4.516.1126.4518.81Price / SalesN/A313.84450.0676.66Price / CashN/A67.8344.0437.47Price / Book2.516.747.634.64Net Income-$209.36M$138.11M$3.18B$245.69M7 Day Performance9.79%-2.04%-1.85%-2.63%1 Month Performance19.82%-1.57%0.19%-2.37%1 Year Performance-26.32%-3.19%17.21%13.64% Syndax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNDXSyndax Pharmaceuticals3.7342 of 5 stars$16.38+2.4%$36.20+121.0%-30.1%$1.40BN/A-4.51110GRFSGrifols2.1379 of 5 stars$7.32-2.0%N/A-11.8%$5.03B$7.13B6.2023,737Upcoming EarningsTGTXTG Therapeutics4.4797 of 5 stars$30.71-0.1%$40.67+32.4%+133.9%$4.78B$233.66M-307.07290Positive NewsKRYSKrystal Biotech4.4767 of 5 stars$153.24-1.6%$206.67+34.9%+63.6%$4.41B$50.70M86.58210Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageSWTXSpringWorks Therapeutics1.2418 of 5 stars$57.43-2.0%$70.83+23.3%+22.8%$4.27B$5.45M-14.80230Earnings ReportAnalyst ForecastInsider TradeNews CoverageBHVNBiohaven3.3776 of 5 stars$41.45-0.8%$63.15+52.4%-15.8%$4.19BN/A-4.43239Short Interest ↓RXRXRecursion Pharmaceuticals1.5231 of 5 stars$10.53+23.9%$8.75-16.9%-17.8%$4.11B$64.60M-6.88400High Trading VolumePTCTPTC Therapeutics3.6197 of 5 stars$51.82+4.3%$58.85+13.6%+93.9%$4.00B$937.82M-8.721,410Analyst ForecastNews CoverageOGNOrganon & Co.4.8637 of 5 stars$15.30-6.3%$20.80+36.0%-15.2%$3.94B$6.26B3.0310,000RAREUltragenyx Pharmaceutical4.6097 of 5 stars$42.49-2.4%$92.43+117.5%-7.1%$3.92B$434.25M-6.571,276Analyst ForecastALVOAlvotech2.6284 of 5 stars$12.99+1.6%$18.00+38.6%-26.7%$3.92B$391.87M-7.021,026News Coverage Related Companies and Tools Related Companies GRFS Alternatives TGTX Alternatives KRYS Alternatives SWTX Alternatives BHVN Alternatives RXRX Alternatives PTCT Alternatives OGN Alternatives RARE Alternatives ALVO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNDX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNDX Stock Alerts